Apellis Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for APLS, updated each market day.
APLS AI Sentiment
AI sees no strong directional signal for Apellis Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: May 20, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Apellis Pharmaceuticals, Inc. Common Stock
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Sector
Exchange
Market Cap
$5,252,712,995
Cap Tier
Employees
733
Headquarters
WALTHAM, MA
Listed Since
Nov. 9, 2017
Website
APLS Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
APLS Volatility
Apellis Pharmaceuticals, Inc. Common Stock has shown low price volatility over the last 5 trading days. Low volatility suggests steady price action with smaller daily moves.
